Aclaris Therapeutics Inc

Aclaris Therapeutics Inc operates a clinicalstage biopharmaceutical company develops novel drug candidates for immuneinflammatory diseases in the United States It operates through two segments Therapeutics and Contract Research The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immunoinflammatory diseases The Contract Research segment engages in the provision of laboratory services The company also develops Zunsemetinib an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis and Hidradenitis suppurativa and ATI1777 a soft JAK 13 inhibitor for the treatment of moderate to severe atopic dermatitis In addition it develops ATI2138 an ITKTXKJAK3 inhibitor as a potential treatment for T cellmediated autoimmune diseases GutBiased Program for inflammatory bowel disease and ATI2231 an MK2 inhibitor treatment for pancreatic and metastatic breast cancer The company was incorporated in 2012 and is headquartered in Wayne Pennsylvania